Insulin zinc mixed human 100units/ml suspension for injection 10ml vials
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Insulin zinc mixed human
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Part of the Humulin brand family (generic: Insulin zinc mixed human)
MHRA licensed products
View all licensed products for Insulin zinc mixed human on the MHRA register
WHO defined daily dose (DDD)
40 unit
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 19 · Randomised trials: 2 · 2008–2026
Showing the 50 most relevant studies, sorted by most relevant.
Samantha Cassar, Marie Misso, Will G. Hopkins, et al.
Human Reproduction, 2016
- Insulin Resistance
- Polycystic Ovary Syndrome
- Glucose Clamp Technique
Alessandro Sanna, Davide Firinu, Patrizia Zavattari, et al.
Nutrients, 2018
- Autoimmunity
- Autoimmune Diseases
- Deficiency Diseases
Fernanda Bellolio, R.M. Gilmore, Latha Ganti
Cochrane Database of Systematic Reviews, 2014
- Blood Glucose
- Diabetes Mellitus
- Hyperglycemia
Janet C. King, Kenneth H. Brown, Rosalind S. Gibson, et al.
Journal of Nutrition, 2016
M. Weickert, A. Pfeiffer
The Journal of nutrition, 2018
Partha Sarathi Swain, S. B. N. Rao, D. Rajendran, et al.
Animal nutrition, 2016
P. Dubey, Vikram Thakur, M. Chattopadhyay
Nutrients, 2020
David Medina-Cruz, Ebrahim Mostafavi, Ada Vernet-Crua, et al.
Journal of Physics Materials, 2020
Gazda P, Glibowski P
2026
- Metabolic Diseases
- Curcumin
- Anthocyanins
Metabolic disorders such as obesity, type 2 diabetes, and lipid disorders are major health challenges worldwide. There is increasing interest in the role of food-derived antioxidants in the context of metabolic disorders due to their documented antioxidant activity. Antioxidants such as flavonoids and polyphenols neutralize reactive oxygen species and reduce oxidative stress, which can affect cell function and metabolic processes. Anthocyanins, curcumin, and resveratrol exhibit physiological and pharmacological properties such as antioxidant, anti-inflammatory, anti-cancer, anti-obesity, and anti-diabetic effects. The main aim of this systematic review is to comprehensively evaluate and synthesize the current scientific evidence on the role of anthocyanins, curcumin, and resveratrol in the prevention and management of metabolic disorders, with a focus on obesity, type 2 diabetes, and dyslipidemia. Databases such as PubMed and Embase were searched, and the final selection included 105 studies that met the inclusion criteria. The analyzed studies demonstrated that anthocyanin supplementation (up to 320 mg/day) was associated with reductions in inflammatory markers such as IL-6 and TNF-α, improvements in HDL cholesterol, and modest reductions in HbA1c (~0.3-0.5%). Curcumin supplementation was associated with decreases in body weight (up to 0.82 kg), BMI (up to 0.30 kg/m2), triglycerides, total cholesterol, and fasting glucose levels. Resveratrol showed mixed but potentially beneficial effects on insulin sensitivity, oxidative stress markers, and lipid metabolism, although the clinical outcomes remained inconsistent across studies. These findings suggest that the antioxidant effects of anthocyanins, curcumin, and resveratrol may be related to their ability to suppress oxidative stress and inflammatory processes, thereby contributing to improvements in glucose and lipid metabolism. The conclusions from this analysis may contribute to a better understanding of the role of antioxidants in the management of metabolic health and indicate directions for future research in this area.
Abstract licence: CC BY
A. Gastaldelli
Obesity (Silver Spring, Md.), 2022
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.